Cellectis ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-23.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.89next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Consolidated Cash, Cash Equivalents, and Fixed-Term Deposits Quarterly188MTarget: Sufficient to fund operations into Q4 2027
Lasme-cel (UCART22) Pivotal Phase 2 BALLI-01 Trial Enrollment QuarterlyTarget: First interim analysis (n=40) expected in Q4 2026
Eti-cel (UCART20x22) Phase 1 NATHALI-01 Trial Enrollment QuarterlyTarget: Full Phase 1 dataset expected in Q4 2026
Watch Items
- Lasme-cel (UCART22) Pivotal Phase 2 BALLI-01 First Interim AnalysisTrigger: Q4 2026 (n=40 patients)Action: Evaluate overall response rate (ORR) and complete remission (CR/CRi) rates against Phase 1 benchmarks (83% ORR at RP2D) to validate pivotal efficacy.
- Eti-cel (UCART20x22) Phase 1 NATHALI-01 Full Dataset ReleaseTrigger: Q4 2026Action: Assess clinical impact of dual-targeting CD20/CD22 CAR-T and evaluate the efficacy/safety of the low-dose IL-2 combination cohort.
- AstraZeneca Research and Collaboration Agreement ProgressTrigger: Ongoing milestone achievements and joint research updatesAction: Monitor collaboration revenue recognition and pipeline progression of joint candidates to sustain cash runway.
Research as of 19 Jun 2026